Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
Completed
Anne Chang
Phase 1/Phase 2
2017-06-21
This is a study to determine whether secukinumab is a potential therapy for those with
papulopustular rosacea. We will observe whether this drug decreases the size and/or amount
and severity of the pustules of those who suffer from rosacea.
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
Active, not recruiting
Janssen Research & Development, LLC
Phase 1
2018-11-19
The purpose of this study is to determine the effect of treatment with guselkumab in
participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
Active, not recruiting
Janssen-Cilag G.m.b.H
Phase 3
2019-02-08
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis
participants who receive on-label guselkumab treatment until week 20 and respond with a
Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of
disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every
16 weeks).
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Recruiting
Belgium Health Care Knowledge Centre
Phase 4
2020-08-20
The main objective of this study is to investigate whether controlled dose reduction of IL17
or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients.
Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be
carried out.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
